5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
GlobeNewswire (Feb 26, 2014)
GlobeNewswire (Feb 10, 2014)
GlobeNewswire (Feb 5, 2014)
GWPH vs. ETF Alternatives
Wednesday, Feb 55:36 AM|Wednesday, Feb 55:36 AM| 6 Comments
Wednesday, Feb 512:05 AM
Tuesday, Feb 45:30 PM
Thursday, Jan 95:25 PM
Thursday, Jan 95:25 PM| 24 Comments
- Medical Marijuana (MJNA +4.3%) is up 25% YTD on the pink sheets as investors continue making speculative bets on pot-related plays following the start of legal marijuana sales in Colorado on Jan. 1.
- On the other hand, several peers gave back a big chunk of their recent gains today: GRNH -52.4%. AVTC -15.8%. MDBX -18.6%. HEMP -24.1%. MWIP -21.9%.
- But GW Pharmaceuticals (GWPH +23.5%), a more established name that yesterday priced a 2.4M-share follow-on offering at $36, went in the other direction.
- With demand outstripping expectations, Colorado is (for now) arguably seeing the marijuana equivalent of the 1970s oil crisis: Long lines, shortages, rationing, and soaring prices have become the norm for licensed dispensaries.
- Words of caution from seasoned investors about putting money into pot plays are easy to find. Fund manager Frank Igarra: "There might be one or two that survive, but having seen crazes like this, people have been burned by them a lot. The average investor should think twice."
- FINRA issued a warning in August about potential marijuana stock scams.
Friday, Jan 34:49 PM
Friday, Jan 34:49 PM| 32 Comments
- Investors apparently have taken the big crowds outside marijuana retailers in Colorado as a harbinger of potential growth in the still-new industry after the state launched the first legal U.S. sale of recreational pot.
- Most of the companies that could benefit are very small, with MediSwipe (MWIP), which sells transaction processing systems to the medical industry, perhaps the most established; others include GreenGro Tech (GRNH), which sells growing systems and equipment popular with pot farmers; Medbox (MDBX), which makes storage and dispensing machines for controlled medicines; and GW Pharmaceuticals (GWPH), which focuses on medicines derived from marijuana.
Wednesday, Dec 112013, 1:46 PM|Wednesday, Dec 112013, 1:46 PM| 1 Comment
Tuesday, Nov 262013, 5:40 PM
Tuesday, Nov 262013, 5:15 PM
Monday, Oct 72013, 12:46 PM|Monday, Oct 72013, 12:46 PM| 5 Comments
Monday, Oct 72013, 9:12 AM
Monday, Oct 72013, 8:00 AM
Monday, Oct 72013, 8:00 AM| 3 Comments
- Lazard Capital is excited about Sativex maker GW Pharmaceuticals (GWPH).
- Market chatter suggests Joshua Schimmer has raised his price target on the shares to $65 (from $22) for upside potential of 163%.
- Apparently, the company's Otsuka-partnered (OTSKF.OB) epilepsy program is "one of the most compelling opportunities [Lazard] has ever seen."
- Here's what the company has to say about that program: "By studying the impact of cannabinoid addition on the amplitude of the epileptiforms produced, researchers are able to recognize if compounds could perform as an anti-epileptic drug in vivo."
Thursday, Oct 32013, 1:16 PM|Thursday, Oct 32013, 1:16 PM| Comment!
Monday, Sep 92013, 12:46 PM|Monday, Sep 92013, 12:46 PM| Comment!
Monday, Aug 52013, 6:17 AM|Monday, Aug 52013, 6:17 AM| Comment!
Monday, Jul 82013, 2:11 PMGW Pharmaceuticals plc (GWPH -0.4%) says that Sativex is now available in Italy as a prescription medicine for the treatment of moderate to severe spasticity in Multiple Sclerosis patients. The launch comes after the company received full marketing authorization for the drug by Italian health authorities in May. |Monday, Jul 82013, 2:11 PM| 1 Comment
Tuesday, Jun 42013, 1:35 PM
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.